Ovarian/Peritoneal/Fallopian Tube Cancer
Show Only Open Trials
1.
Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Metastatic Epithelial Cancer
2.
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Previously Treated, Metastatic Ovarian, Fallopian Tube or Primary Peritoneal Cancer
3.
Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
- Study Status: Open to Enrollment
- Sponsor: NCI
- Disease Status and/or Stage: Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
4.
A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL
- Study Status: Open to Enrollment
- Sponsor: Gynecologic Oncology Group; National Cancer Institute
- Disease Status and/or Stage: Locally Advanced Cervical Cancer
5.
Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Montefiore Medical Center
- Disease Status and/or Stage: Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
6.
A randomized phase III trial of paclitaxel plus carboplatin versus ifosfamide plus paclitaxel in chemotherapy naïve patients with newly diagnosed stage I-IV, persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus or ovary
- Study Status: Open to Enrollment
- Sponsor: Gynecologic Oncology Group/NIH/NCI
- Disease Status and/or Stage: Newly Diagnosed, Stage I-IV, Persistent or Recurrent Uterine or Ovarian Cancer
7.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Open to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
8.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
